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ABSTRACT: There is an urgent need to understand the behavior
of the novel coronavirus (SARS-COV-2), which is the causative
agent of COVID-19, and to develop point-of-care diagnostics.
Here, a glyconanoparticle platform is used to discover that N-acetyl
neuraminic acid has affinity toward the SARS-COV-2 spike
glycoprotein, demonstrating its glycan-binding function. Optimi-
zation of the particle size and coating enabled detection of the
spike glycoprotein in lateral flow and showed selectivity over the
SARS-COV-1 spike protein. Using a virus-like particle and a
pseudotyped lentivirus model, paper-based lateral flow detection
was demonstrated in under 30 min, showing the potential of this
system as a low-cost detection platform.
In December 2019, a novel zoonotic coronavirus (SARS-COV-2), reported in Wuhan (China), led to a pandemic of
the respiratory disease COVID-19.1 There are currently few
therapeutics and no vaccine. Diagnostics, surveillance, and case
isolation are the primary tools for controlling the spread of the
virus and driving down the basic reproduction (R0) value.
Following the successful genome sequencing of SARS-COV-2,
RT-PCR-based (reverse transcription polymerase chain
reaction) diagnostics were rapidly developed. These require
dedicated laboratory facilities, trained personnel, and do not
provide an instant output, and while highly specific, false-
negative results are reported at 3% versus chest CT scans.2
There are also reports of conflicting RT-PCR results in
samples from the same patient.3,4 The results can depend on
the sampling location (i.e., throat versus lower respiratory
tract),5 and the false-negative rate is highest during the early
stages of infection.6
An alternative detection platform to RT-PCR is the lateral
flow device (LFD), such as the home-pregnancy test,7 which
typically uses antibodies as the detection units immobilized to
both the stationary phase (e.g., nitrocellulose paper) and the
mobile phase (e.g., gold nanoparticle), forming a “sandwich”
with the analyte. Test lines show a positive (red line) response
by eye. Such LFDs require little or no clinical infrastructure or
training, and they can be used in the patient’s home. The cost-
effectiveness of these inexpensive devices has been demon-
strated by various studies of malaria rapid diagnostic tests8,9
and were found to compare well to the more expensive RT-
PCR for Ebola diagnosis.10 In addition to antibodies, other
biological recognition units such as nucleic acids,11 glycans,
and lectins12 could be used. Glycans have not been widely
applied in lateral flow13 but offer new opportunities and
advantages compared with antibody-based systems. Glycans
have reduced cold chain needs compared with proteins14 and
are thus suited to low resource, triage, or emergency settings. A
further benefit of glycans, as the capture unit, would be the
detection of intact viruses. For SARS-COV-2, viral RNA (e.g.,
from a positive RT-PCR result) is detected past the point
where patients are no longer infectious, resulting in extended
hospital stays.15
Glycans (carbohydrates) direct myriad binding and
recognition events in biology from cell−cell communication
to being markers of disease. Analysis of the 2009 swine
(zoonotic) influenza pandemic showed that porcine viral
hemagglutinins, which normally bind α2,3′-linked sialic acids,
switched to binding α2,6′-linked sialic acids found in human
respiratory tracts.16,17 This demonstrates the importance of
glycan-binding during infection. This switch in glycan
specificity has enabled the establishment of glycan-functional
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biosensors to rapidly identify strains without using nucleic acid
based detection methods.18,19 All coronaviruses display
homotrimers of spike glycoproteins on their surface. Sialic
acid binding by the S1 spike protein subunits is crucial for
coronavirus to engage host cells, while the S2 domain initiates
viral fusion.20 Tortorici et al. showed the structural basis for 9-
O-acetylated sialic acid binding to a human coronavirus (strain
OC43) by cryo-EM, and affinity to this ligand to the HKU1-
HE strain, has also been reported.21,22 MERS S1 preferentially
binds α2,3′-linked over α2,6′-linked sialic acids but any
acetylation of the sialic acids decreases affinity,23 which is
distinct from OC43. This evidence shows that sialic acid
binding is crucial in coronavirus infection and potentially in its
zoonosis to human hosts,23,24 but that the exact glycan partner
can vary between strains. It has also emerged that sulfated
glycosaminoglycans (including heparin sulfates) bind SARS-
COV-2 spike protein, and can inhibit viral entry.25−27 The
above examples demonstrate that glycan “anchoring” of
coronaviruses may offer opportunities for detection using
capture techniques such as LFD.
Individual glycans display low affinity to their protein
targets, but this is overcome in nature by multivalent display.
Due to the cluster glycoside effect,28 displaying multiple copies
of glycans can result in several orders of magnitude
enhancement in the observed affinity. This has been widely
exploited in materials chemistry29,30 using dendrimers,31,32
peptides/proteins,33 polymers,34,35 and nanoparticles19,36 to
generate high avidity.
Here we report the synthesis of polymer-stabilized, multi-
valent gold nanoparticles bearing sialic acid derivatives and
their interaction with the spike glycoprotein from SARS-COV-
2. We find that α,N-acetyl neuraminic acid binds the spike
glycoprotein and subsequently exploit this interaction as the
detection unit in a prototype lateral flow rapid diagnostic,
which requires no centralized infrastructure.
Figure 1A shows the sequence alignments between the S1
domains of coronavirus spike proteins from MERS and SARS-
COV-2. There is some conservation of the sialic acid binding
site, notably residues His69 and Phe79. Figure 1B,C shows
models constructed from the Cryo-EM structure of SARS-
COV,37 with missing loops and the α2,3′-sialyllactose modeled
into it using the Cryo-EM structure of MERS.38 The modeling
data suggests that Arg21 and Leu24 coordinates the glycan,
while Gln23 may also have a role in binding. Adjacent to the
hairpin containing His69 and Phe79, it seems likely that
Arg246 also has a role in coordination. The limited
conservation of the sialic acid binding groove sequence (S21,
Supporting Information (SI)) is in marked contrast to the
entirety of the spike S protein, which is often highly conserved
between coronaviruses.39 In the MERS sialic acid binding site
in complex with α2,3′-sialyllactose, only the neuraminic acid
unit, not the lactose, is engaged. This is in contrast to influenza
hemagglutinins, which contact the galactose residues.40 This
evidence suggests that N-acetyl neuraminic acid is a reasonable
target for SARS-COV-2 binding (also hypothesized here41)
and hence a potential capture ligand for a new “glyco-LFD”
diagnostic device.
Figure 2A shows a design schematic for a glyco-LFD.
Typical LFDs use antibodies, but here the glycan is
immobilized (as a BSA-glycoconjugate) on the test strip and
also in the mobile phase onboard gold nanoparticles, providing
multivalency (and hence affinity), for dissecting SARS-COV-2
binding and for the LFD. Our nanoparticle design concept uses
telechelic polymer tethers which conjugate the glycans, by
displacement of an ω-terminal pentafluorophenyl (PFP)
group, and immobilization onto gold particles via the α-
Figure 1. (A) Sequence alignment between the S1 domains of the
SARS-COV-2 and MERS spike proteins. Regions important for sialic
acid binding are highlighted by red boxes; (B) Model showing the
hypothesized sialic acid binding sites (yellow CPK coloring) for the
SARS-COV-2 spike protein trimer; (C) A comparison between the
sialic acid binding sites from MERS (PDB entry 6Q04) and the
SARS-COV-2 model (PDB entry 6VSB) in complex with a2,3′-
sialyllactose.
Figure 2. Design concept for glyco-lateral flow devices. (A) Lateral
flow assay for virus, using glycan capture units; (B) Synthetic
procedure for glyconanoparticles.
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terminal thiol. Poly(N-hydroxyethyl acrylamide), PHEA, was
chosen as the polymer to give colloidally stable particles and as
an acrylamide, it is not easily hydrolyzable unlike acrylates for
example, Figure 2B and Table 1.36,42 PHEA was synthesized
using RAFT (reversible addition−fragmentation chain trans-
fer) polymerization resulting in dispersities below 1.3. The
PHEA lengths were selected on the basis of performance in
initial lateral flow screening assays (data not shown) and from
reports of their colloidal stability.36,42 Amino-glycans were
synthesized by reduction of anomeric azides and subsequently
conjugated to the PHEAs by displacement of the PFP group,
which was confirmed by 19F NMR. Polymers were then
assembled onto citrate-stabilized gold nanoparticles and excess
ligand removed by centrifugation/resuspension cycles. The
nanoparticles were characterized by UV−vis, dynamic light
scattering (DLS), transmission electron microscopy (TEM),
and XPS (x-ray photoelectron spectroscopy) to confirm
surface coating (Table 2 and SI). Following observations via
DLS and UV−vis that 16 nm sialyllactose particles were less
stable than 35 nm particles, the latter were selected for initial
glycan-binding assays.
With the glyconanoparticles on hand, recombinant S1
subunit (SARS-COV-2,S1) spike protein was immobilized
onto biolayer interferometry (BLI) sensors19 to replicate a
lateral flow situation, which is the primary aim of this work.
Since there are 22 N-linked glycans per protein which are not
present in bacteria-expressed protein,44 we used protein
expressed in mammalian cells (HEK) to ensure glycosylation.
Figure 3A shows α,NeuNAc-AuNPs bind to a greater extent
compared to both sialyllactose isomers (α2,3′/α2,6′) and the
monosaccharide control (glucose). X-ray photoelectron spec-
troscopy analysis (SI) of these particles revealed that the
NeuNAc/Glc monosaccharide-terminated polymers had a
higher grafting density than the sialyllactose trisaccharides by
a ratio of 2:1 (35 nm)/ 3:1 (16 nm) because of the difference
in glycan size. It is therefore important to note that this data
does not rule out sialyllactose binding (and indeed, in LFD, we
do see binding), but that in this system, NeuNAc gave the
strongest response and consequently was taken forward.
Thermal shift assays further confirmed that NeuNAc bound
selectively over galactose and glucose, and preliminary STD
(saturation transfer difference) NMR spectroscopy showed
NeuNAc binding also (both in SI). While outside the scope of
this work, the identification of the sialic acid binding function
of the spike protein may provide fundamental guidance as to
how the virus engages host cells, or is processed within them,
and this (to the best of our knowledge) is the first report of
this matter.
The next step was to evaluate the impact of particle size on
binding. Both 16 and 35 nm gold (relevant diameters for
LFDs) NeuNAc particles were used to interrogate SARS-
COV-2,S1, Figures 3B,C. End-point dose dependency (Figure
3D) showed similar binding trends for both particles, with an
apparent Kd ∼ 1 nM, noting that for multivalent systems exact
Kd’s cannot be extracted. The plots are shown in terms of OD
(SPR absorption maximum) as this is standard for AuNP
concentration.
With the successful identification of NeuNAc as a target
ligand, its application as the capture unit in lateral flow was
examined. The performance of an LFD depends on not only
the affinity of the capture ligand (NeuNAc) but also the flow
of the particles. “Half” lateral flow assays (Figure 4A) were
established to optimize the particles. The negative test line was
(commercial) 2,3′-sialyllactose-BSA, which the glyco-nano-
particle should not bind to (to avoid false positives in “full”
lateral flow where it would serve to capture viral antigen). The
Table 1. Polymer Characterization
code
M:CTA
(−)
MN(theo)
a
(g mol−1)
MN(SEC)
b
(g mol−1)
MN(NMR)
c
(g mol−1)
Đb
(−)
PHEA40 20 2800 5100 5000 1.19
PHEA50 25 3400 6400 5500 1.27
PHEA58 30 4000 7200 6700 1.26
aEstimated from [M]:[CTA]. bFrom DMF SEC versus PMMA
standards. c1H NMR end-group analysis.
Table 2. Nanoparticle Characterization
code UVmaxa (nm) ASPR/A450
b (−) Dh(UV)c (nm) Dh (DLS)d (nm) D(TEM) (nm)
AuNP16 519 1.64 16 20.7 ± 0.8 14 ± 2
NeuNAc-PHEA40AuNP16 527 1.66 16 40.9 ± 0.5 (−)
NeuNAc-PHEA50AuNP16 526 1.68 18 44.2 ± 0.8 (−)
AuNP35 526 1.91 35 34.5 ± 0.5 35 ± 3
NeuNAc-PHEA40AuNP35 531 1.98 45 46.2 ± 0.7 (−)
NeuNAc-PHEA50AuNP35 531 1.99 45 55.3 ± 0.8 (−)
aSPR absorption maximum. bAbsorbance ratio of SPR to 450 nm. cEstimated from UV−vis;43 dFrom dynamic light scattering. eFrom TEM, from
an average of >100 particles, showing ± SD.
Figure 3. Biolayer interferometry analysis of SARS-COV-2 spike
protein with glyconanoparticles. (A) Screening using PHEA50@
AuNP35 at OD = 1; Dose-dependent binding of NeuNAc-PHEA50
using (B) @AuNP16 and (C) @AuNP35. OD = 1 (−), 0.5(-), 0.25(-),
0.125(-); (D) Binding curves.
ACS Central Science http://pubs.acs.org/journal/acscii Research Article
https://dx.doi.org/10.1021/acscentsci.0c00855
ACS Cent. Sci. XXXX, XXX, XXX−XXX
C
positive control was immobilized SARS-COV-2,S1 (which
mimics capture in full lateral flow) and the nanoparticles were
flowed over them (original lateral flow strips are in SI).
Pleasingly, all particles bound SARS-COV-2,S1 showing this
detection method is valid. NeuNAcPHEA50@AuNP35 gave the
strongest signal-to-noise compared to other particles, owing to
their lower background compared to 16 nm particles (noting
that the 16 nm did give a strong signal too). The 16 nm also
showed some binding to the 2,3′-sialyllactose-BSA control
however. Hence, NeuNAcPHEA50@AuNP35 particles were
used from this point onward, Figure 4B/C. Both α2,3′- and
α2,6′-sialiyllactosamine particles were also tested, and on larger
AuNPs (55−70 nm) and longer polymers (PHEA72) too, but
gave no improvement over NeuNAcPHEA50@AuNP35. Block-
ing of the NeuNAc particles with BSA before running was also
explored in an attempt to further reduce the background, as is
common in LFDs. BSA blocking did not improve the
performance of the NeuNAc systems, but it did reduce off-
target binding in the α2,3′-sialyllactosamine systems tested.
Encouraged by these results, the specificity and function of the
NeuNAcPHEA50@AuNP35 particles were tested against a
panel of test-line immobilized lectins [1 mg·mL−1]. Total
signal intensity is plotted in Figure 4D, confirming that
NeuNAc-AuNPs have no nonspecific binding. The only lectin
that bound was RCA120, which is known to have some affinity
toward sialic acids.45 WGA and SNA also have some affinity to
sialic acids but did not show signal here, highlighting an
advantage (and challenge) of LFD, that glycan presentation is
a strong determinant of the signal generation in addition to
binding affinity. To test binding specificity in a more
challenging scenario, the particles were screened against the
spike protein, SARS-COV-2,S1, (the desired target) and also
against the S1 spike domain of a previous zoonotic coronavirus
SARS-COV-1,24 responsible for the 2003 “SARS” outbreak. As
can be seen in Figure 4E, the NeuNAc particle system has a
clear preference for SARS-COV-2, demonstrating selectivity in
this glyconanoparticle system. While this does not rule out
binding, it does show the particles/glycan do not generate
sufficient signal against SARS-COV-1. This data further
supports the notion that the terminal NeuNAc is the key
binding motif.
To explore the detection limits and specificity of this system,
NeuNAc (positive) and galactose (negative) nanoparticles
were screened against a dilution series of SARS-COV-2,S1
(Figure 5A,B). At the highest concentration (0.5 mg·mL−1)
galactose particles showed weak binding to SARS-COV-2,S1.
NeuNAc particles showed significantly stronger binding, with
an apparent limit of detection below 8 μg·mL−1 or 8 nM.
Encouraged by successful binding, a dipstick sandwich assay
was established where the analyte was added to the gold
particle solution, rather than dried onto the nitrocellulose
paper. The test line was NeuNAc-BSA (validated to capture
the particles by BLI, SI) and RCA120 as a control line, which is
essential in lateral flow devices to ensure each device is
functional. To mimic the virus in a model system without cell
debris, which may complicate initial LFD development, the
spike glycoprotein was immobilized onto 100 nm polystyrene
nanoparticles which match the diameter of the coronavirus.
Figure 5C shows the results of testing this system (original
lateral flow strips with no image enhancement are in the SI). In
this system, 2,3′-sialyllactose-BSA is the test (capture) line as
the data in Figure 4 confirmed no nonspecific binding by the
nanoparticles to this line. The lateral flow devices could clearly
detect the virus-like particles at a concentration of just 5 μg·
mL−1 (5 nM) protein, which is in line with the detection limits
from Figure 5B. Controls using naked polystyrene colloids
showed no binding to the test line, ruling out nonspecific
interactions, and a control (with no polystyrene analyte) only
showed control line binding. The resolution of the test spots
could be further enhanced using a silver-staining protocol,46
which improves the “by eye” detection (Figure 5C). An
additional control of two influenza strains (which bind
sialyllactoses) were shown to have little off-target binding as
influenza hemagglutinins require the galactose linker in
addition to the sialic acid, for strong binding (SI).40 As a
final proof of concept, SARS-COV-2 spike protein pseudo-
typed lentivirus were tested in half-lateral flow. Pseudovirus
was applied to the test line and ran in a lateral flow cassette (SI
for full photos). Using NeuNAc particles, detection at 1.5 ×
104 transduction units/mL was achieved. Galactose-functional
particles failed to detect the virus, confirming the role of sialic
acid binding. Direct comparison of transduction units/mL to
viral load (typical copies/mL) is not possible, but values as
high as 108 copies·mL−1 are reported from COVID positive
swabs,15 suggesting this method may have relevant detection
limits. A hybrid LFD using antibody capture in one component
may also be possible to further improve this.13
In conclusion, we have demonstrated a glycan-based lateral
flow detection system that can detect the spike glycoprotein
from the SARS-COV-2 virus in under 30 min. Guided by
sequence alignment against other coronavirus spike proteins, it
was hypothesized that sialic acids may bind this protein, to
Figure 4. Half lateral flow analysis of NeuNAcPHEAx@AuNPy
particles. (A) Half lateral flow assay setup with target protein
immobilized on the test line; (B) Effect of polymer chain length and
particle size on lateral flow binding; (C) Signal:noise analysis; (D)
Selectivity of NeuNAcPHEA50@AuNP35 against a panel of lectins
(inset example LFD strips). (E) Selectivity of NeuNAcPHEA50@
AuNP35 against S1 protein from different coronavirus strains. Data is
the mean from 3 repeats. Original LFD strips are in the SI. Test lines
are within the dashed-line box. 2,3′SL-BSA = 2,3′-sialyllactose-
functionalized BSA.
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enable capture/detection. Using a nanoparticle-based biolayer
interferometry platform, we demonstrated that α,N-acetyl
neuraminic acid is a ligand for the spike glycoprotein. The gold
nanoparticles and polymer tethers (for glycan capture) were
optimized, and it was found in “half sandwich” lateral flow
assays that α,N-acetyl neuraminic acid particles have selectivity
toward the SARS-COV-2 spike protein, including specificity
over SARS-COV-1 and a panel of lectins. Guided by this, we
successfully detected a virus mimic particle bearing SARS-
COV-2,S1 in under 30 min, with a detection limit of the spike
protein around 5 μg·mL−1. Furthermore, a SARS-COV-2 spike
protein-presenting pseudotyped lentivirus was successfully
detected in a robust proof-of-concept. This work provides
proof that glycan binding can be exploited to create rapid
point-of-care diagnostics in a format which requires no
infrastructure and limited training and, to the best of our
knowledge, is the first reported all-glycan lateral flow system.
This approach may find application for disease surveillance or
mass testing at transport/work hubs or even for self/home
testing. Finally, the observation that SARS-COV-2 can engage
sialic acids found on human respiratory cells may provide
insight into its zoonosis and infection pathways to help guide
new interventions.
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